Arrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024. In the quarter to June 2026, revenue grew 171.0%, EPS fell 7.94%, free cash flow fell 15.4% and total debt rose 259.5%, each against the same quarter a year earlier.
Follow ARWR
Arrowhead Pharmaceuticals, Inc. (ARWR) EV/Sales
As of 16 October 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a EV/Sales of 10.9×. Over the past ten years it has ranged from −45.0× (December 2016) to 2,591× (August 2016); the current reading is higher than 21% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.8× | (57.65%) |
| FY2024 | 11.2× | (2.73%) |
| FY2023 | 11.6× | (11.87%) |
| FY2022 | 13.1× | (70.44%) |
| FY2021 | 44.4× | (3.45%) |
| FY2020 | 45.9× | 224.71% |
| FY2019 | 14.1× | (85.09%) |
| FY2018 | 94.9× | 1,022.60% |
| FY2017 | 8.5× | (99.63%) |
| FY2016 | 2,308× | 279.92% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 16.4× | 26.73% |
| Mar 2026 | 12.9× | 67.92% |
| Dec 2025 | 7.7× | 61.43% |
| Sep 2025 | 4.8× | 78.60% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CAI Caris Life Sciences,�Inc. compare | 8.3× |
| TGTX TG Therapeutics, Inc. compare | 9.8× |
| AXSM Axsome Therapeutics, Inc. compare | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. | 10.9× |
| PTGX Protagonist Therapeutics, Inc. compare | 27.4× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| CYTK Cytokinetics, Incorporated compare | 121× |
| SYRE Spyre Therapeutics, Inc. compare | 5,336× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)